[1] E. Patouillard, J. Griffin, S. Bhatt, A. Ghani, and R. Cibulskis, “Global investment targets for malaria control and elimination between 2016 and 2030,” BMJ Glob. Heal., vol. 2, no. 2, p. e000176, May 2017.
[2] WHO, “Global report on antimalarial drug efficacy and drug resistance: 2000-2010,” Who, p. 115, 2010.
[3] A. Mohammed et al., “Trends in chloroquine resistance marker , Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania,” Malar. J., vol. 12, no. 1, p. 1, 2013.
[4] M. NDEJEMBI et al., “Therapeutic Efficacy of Sulfadoxine-Pyrimethamine and Prevalence of Resistance Markers in Tanzania Prior To Revision of Malaria Treatment Policy: Plasmodium Falciparum Dihydrofolate Reductase and Dihydropteroate Synthase Mutations in Monitoring in Vivo Re,” Am. J. Trop. Med. Hyg., vol. 71, no. 6, pp. 696–702, 2018.
[5] G. M. Mubyazi and M. A. Gonzalez-Block, “Research influence on antimalarial drug policy change in Tanzania: Case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug,” Malar. J., vol. 4, pp. 1–13, 2005.
[6] Y. P., C. J.L., A. S., A. J., L. P.S., and M. J., “Trends in availability and prices of subsidized ACT over the first year of the AMFm: Evidence from remote regions of Tanzania,” Malar. J., vol. 11, p. 299, 2012.
[7] K. Mugittu et al., “Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies,” Malar J, vol. 4, 2005.
[8] D. R. Brooks, P. Wang, M. Read, W. M. Watkins, P. F. G. Sims, and J. E. Hyde, “Sequence Variation of the Hydroxymethyldihydropterin Pyrophosphokinase: Dihydropteroate Synthase Gene in Lines of the Human Malaria Parasite, Plasmodium falciparum, with Differing Resistance to Sulfadoxine,” Eur. J. Biochem., vol. 224, no. 2, pp. 397–405, 1994.
[9] T. Triglia, J. G. T. Menting, C. Wilson, and A. F. Cowman, “Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum,” Proc. Natl. Acad. Sci. U. S. A., vol. 94, no. 25, pp. 13944–13949, 1997.
[10] V. Baraka et al., “High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania,” Malar. J., vol. 14, no. 1, pp. 1–9, 2015.
[11] K. Mugittu et al., “Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo re,” Am. J. Trop. Med. Hyg., vol. 71, no. 6, pp. 696–702, 2004.
[12] R. A. Kavishe et al., “Molecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania,” Malar. J., vol. 15, no. 1, pp. 1–8, 2016.
[13] “IT Committee: This Friday we have two items on our agenda. 1. Al Wysocki,” p. 226, 2017.
[14] S. J. Rogerson, V. Mwapasa, and S. R. Meshnick, “Malaria in pregnancy: Linking immunity and pathogenesis to prevention,” Am. J. Trop. Med. Hyg., vol. 77, no. SUPPL. 6, pp. 14–22, 2007.
[15] R. Gana, F. Leke, and L. Slutsker, “WHO Evidence Review Group on Intermittent Screening and Treatment (ISTp) and ACT Treatment of Malaria in Pregnancy,” no. September, pp. 1–17, 2015.
[16] TMIS, “Tanzania Malaria Indicator Survey (TMIS) 2017,” 2017.
[17] The united republic of Tanzania standard treatment guidelines and essential medicines list, 2013.
[18] U. MalariaGEN Resource Centre members based at the Wellcome Trust Sanger Institute, “Protocol for collecting dried blood spots from malaria patients, for the purposes of sequencing Plasmodium parasites.,” https://www.malariagen.net/network/capacity-building/methods#DBS.
[19] S. O. Oyola et al., “Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification,” Malar. J., vol. 15, no. 1, pp. 1–12, 2016.
[20] Z. Shen et al., “MPprimer: A program for reliable multiplex PCR primer design,” BMC Bioinformatics, vol. 11, 2010.
[21] D. T. R. Minja et al., “Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania,” Emerg. Infect. Dis., vol. 19, no. 9, pp. 1446–1454, 2013.
[22] A. M. McCollum, K. Mueller, L. Villegas, V. Udhayakumar, and A. A. Escalante, “Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America,” Antimicrob. Agents Chemother., vol. 51, no. 6, pp. 2085–2091, 2007.
[23] I. Naidoo and C. Roper, “Mapping ‘partially resistant’, ‘fully resistant’, and ‘super resistant’ malaria,” Trends Parasitol., vol. 29, no. 10, pp. 505–515, 2013.
[24] W. E. Harrington, R. Morrison, M. Fried, and P. E. Duffy, “Intermittent Preventive Treatment in Pregnant Women Is Associated with Increased Risk of Severe Malaria in Their Offspring,” PLoS One, vol. 8, no. 2, pp. 2–7, 2013.
[25] World Health Organization (WHO), “World Malaria Report,” 2019.
[26] W. P. Mikomangwa, M. Oms, E. Aklillu, and A. A. R. Kamuhabwa, “Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region,” BMC Pregnancy Childbirth, vol. 19, no. 1, pp. 1–11, 2019.